Semantic Scholar uses AI to extract papers important to this topic.
Raxibacumab is a monoclonal antibody against protective antigen, which is the cell-binding part of Bacillus anthracis… Expand Anthrax, caused by Bacillus anthracis (B anthracis), poses a potential threat as a bioterror agent because after inhalation, the… Expand On December 14, 2012, the FDA approved Raxibacumab, the first monoclonal antibody product developed under Project BioShield to… Expand BackgroundLethal and edema toxin contribute to shock and lethality with Bacillus anthracis. We showed previously in a 96-h… Expand Anthrax is a highly contagious and potentially fatal human disease caused by Bacillus anthracis, an aerobic, Gram-positive, spore… Expand ABSTRACT Although antibiotics treat bacteremia in inhalational anthrax, pathogenesis is mainly driven by bacterial exotoxins… Expand Inhaled Bacillus anthracis spores germinate and the subsequent vegetative growth results in bacteremia and toxin production… Expand Importance of the field: Inhalational anthrax is a disease with a high lethality potential and current therapeutic interventions… Expand BACKGROUND
Inhalational anthrax caused by Bacillus anthracis is associated with high mortality primarily due to toxin-mediated… Expand Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently… Expand